Wenxiu Han1, Yi Qiao2, Hailiang Zhang1, Chunmei Geng1, Xing Zhu3, Dehua Liao4, Yujin Guo1, Mengqi Yang1, Dan Chen1, Pei Jiang5. 1. Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, 6, Jiankang Road, Jining, 272011, China. 2. Department of Public Health, Jining Medical University, 272000, Jining, China. 3. Department of Medical Engineering, Jining Medical University, 272000, Jining, China. 4. Department of Pharmacy, Hunan Cancer Hospital, Central South University, Changsha, 410011, China. 5. Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, 6, Jiankang Road, Jining, 272011, China. jiangpeicsu@sina.com.
Abstract
BACKGROUND: Systemic inflammation has been implicated in the pathogenesis of moyamoya disease (MMD). Sortilin is a critical regulator of proinflammatory cytokine secretion in several cell types. The present study investigated the association between circulating sortilin and proinflammatory cytokine levels and the occurrence of MMD. METHODS: Forty-two MMD cases and 76 age- and sex-matched controls were enrolled in this study between January 2018 and June 2019 at the Affiliated Hospital of Jining Medical University. The demographic and clinical characteristics were evaluated, and the circulating serum and cerebrospinal fluid (CSF) levels of sortilin, sortilin-related receptor with A-type repeats (SorLA), and proinflammatory cytokines including C-reactive protein (CRP), interleukin (IL)-6, interferon (IFN)-γ were measured by enzyme-linked immunosorbent assay. Linear regression and correlation analyses were used to estimate the associations between sortilin, SorLA, and proinflammatory cytokine levels. RESULTS: MMD patients had higher serum levels of sortilin (P = 0.012), CRP (P = 0.013), IL-6 (P = 0.004), and IFN-γ (P = 0.033) than healthy controls. In MMD patients, serum sortilin was positively correlated with serum proinflammatory cytokines (CRP: r = 0.459, P = 0.0022; IL-6: r = 0.445, P = 0.0032; and IFN-γ: r = 0.448, P = 0.0029) and CSF sortilin (r = 0.440, P = 0.0035); the latter was positively correlated with CSF levels of CRP (r = 0.542, P = 0.0002), IL-6 (r = 0.440, P = 0.0036), and IFN-γ (r = 0.443, P = 0.0033). CONCLUSIONS: Elevated sortilin level is associated MMD onset and may be a clinically useful biomarker along with proinflammatory cytokine levels.
BACKGROUND: Systemic inflammation has been implicated in the pathogenesis of moyamoya disease (MMD). Sortilin is a critical regulator of proinflammatory cytokine secretion in several cell types. The present study investigated the association between circulating sortilin and proinflammatory cytokine levels and the occurrence of MMD. METHODS: Forty-two MMD cases and 76 age- and sex-matched controls were enrolled in this study between January 2018 and June 2019 at the Affiliated Hospital of Jining Medical University. The demographic and clinical characteristics were evaluated, and the circulating serum and cerebrospinal fluid (CSF) levels of sortilin, sortilin-related receptor with A-type repeats (SorLA), and proinflammatory cytokines including C-reactive protein (CRP), interleukin (IL)-6, interferon (IFN)-γ were measured by enzyme-linked immunosorbent assay. Linear regression and correlation analyses were used to estimate the associations between sortilin, SorLA, and proinflammatory cytokine levels. RESULTS: MMD patients had higher serum levels of sortilin (P = 0.012), CRP (P = 0.013), IL-6 (P = 0.004), and IFN-γ (P = 0.033) than healthy controls. In MMD patients, serum sortilin was positively correlated with serum proinflammatory cytokines (CRP: r = 0.459, P = 0.0022; IL-6: r = 0.445, P = 0.0032; and IFN-γ: r = 0.448, P = 0.0029) and CSF sortilin (r = 0.440, P = 0.0035); the latter was positively correlated with CSF levels of CRP (r = 0.542, P = 0.0002), IL-6 (r = 0.440, P = 0.0036), and IFN-γ (r = 0.443, P = 0.0033). CONCLUSIONS: Elevated sortilin level is associated MMD onset and may be a clinically useful biomarker along with proinflammatory cytokine levels.
Authors: Fenghua Hu; Thihan Padukkavidana; Christian B Vægter; Owen A Brady; Yanqiu Zheng; Ian R Mackenzie; Howard H Feldman; Anders Nykjaer; Stephen M Strittmatter Journal: Neuron Date: 2010-11-18 Impact factor: 17.173
Authors: Mads Kjolby; Olav M Andersen; Tilman Breiderhoff; Anja W Fjorback; Karen Marie Pedersen; Peder Madsen; Pernille Jansen; Joerg Heeren; Thomas E Willnow; Anders Nykjaer Journal: Cell Metab Date: 2010-09-08 Impact factor: 27.287
Authors: Mario J Aragon; Lauren Topper; Christina R Tyler; Bethany Sanchez; Katherine Zychowski; Tamara Young; Guy Herbert; Pamela Hall; Aaron Erdely; Tracy Eye; Lindsey Bishop; Samantha A Saunders; Pretal P Muldoon; Andrew K Ottens; Matthew J Campen Journal: Proc Natl Acad Sci U S A Date: 2017-02-21 Impact factor: 11.205
Authors: L Jacobsen; P Madsen; S K Moestrup; A H Lund; N Tommerup; A Nykjaer; L Sottrup-Jensen; J Gliemann; C M Petersen Journal: J Biol Chem Date: 1996-12-06 Impact factor: 5.157